all report title image

BIODEFENSE MARKET ANALYSIS

Biodefense Market, By Product (Anthrax, Small Pox, Botulism, Radiation, and Others), By End User (Hospitals, Ambulatory Care Centers, Research Organizations, Military, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Jun 2024
  • Code : CMI4516
  • Pages :167
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Key Developments

  • On 16 January 2024, The UK and the US have launched a Strategic Dialogue on Biological Security to address growing biological threats. This partnership, building on The Atlantic Declaration, aims to enhance collaboration in research, bio-surveillance, innovation, and countermeasures against biological risks.
  • Governor Kathy Hochul, first female Governor of New York State. has initiated the third round of applications for New York's US$40 million Biodefense Commercialization Fund. This fund aims to speed up the development and commercialization of life science innovations addressing infectious disease threats, while fostering job creation and growth in New York's life science sector. Since its launch in September 2021, Empire State Development has granted US$25.3 million to 11 start-ups and 13 academic institutions working on diagnostics, vaccines, therapeutics, and other solutions against infectious diseases.
  • In June 2022, Emergent BioSolutions Inc. revealed that the United States Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) for review.
  • In May 2022, Emergent BioSolutions Inc. also announced its definitive agreement with Chimerix, Inc. to acquire exclusive worldwide rights to TEMBEXA (brincidofovir), the first antiviral approved by the FDA for treating smallpox across all age groups.
  • In February 2022, Appili Therapeutics Inc. unveiled funding exceeding $10 million to progress its biodefense vaccine candidate, ATI-1701, aimed at preventing Francisella tularensis infection. This financial support is anticipated to enhance the company's visibility and stimulate expansion within the Biodefense Market.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.